Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 2 SUPPL. 1, 1999, Pages 77-81

  Walenga, Jeanine M ^a   Jeske, Walter P ^a   Wallis, Diane E ^a   Bakhos, Mamdouh ^a   Lewis, Bruce E ^a   Leya, Fred ^a   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiplatelet agent; Argatroban; Heparin; Platelets; Reo Pro ; Thrombin inhibitor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ARGATROBAN; CLOPIDOGREL; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LEPIRUDIN; PADGEM PROTEIN; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN;

ADULT; AGED; ANTICOAGULATION; CASE REPORT; CONFERENCE PAPER; DRUG EFFICACY; FEMALE; HEPARINIZATION; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ANTITHROMBINS; BLOOD PLATELETS; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN; HIRUDIN THERAPY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOCYTOPENIA; TYROSINE;

EID: 0032895104     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Ferguson TJ. Meeting highlights: The 1995 European Society of Cardiology. Circulation 1995;92:2359-2363
2. Lewis BE, Preliminary results of a prospective randomized controlled trial of argatroban vs. conventional therapy for heparin-induced thrombocytopenia. Presented at the Argatroban-A Novel Antithrombolic Drug for the Treatment of Heparin-Induced Thrombocytopenia Symposium, Florence, Italy, June 12, 1997
3. Wallis DE, Lewis BE, Walenga JM. Failure of current strategies in the prevention of thrombosis in patients with heparin-induced thrombocytopenia. A clinician's perspective. Semin Thromb Hemostas 1999; 25(Suppl 1):3-8
4. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-507
5. Fareed J, Yang LH, Hoppensteadt D, Koza M, Walenga JM, Welzel D, Glycoprotein IIb/IIIa inhibitors can prevent heparin-mediated platelet activation in heparin-induced thrombocytopenia. Circulation 1996;94(Suppl 1):1228(Abst)
6. Jeske WP, Walenga JM, Szatkowski E, et al. Effect of glycoprotein IIb/IIIa antagonists on the HIT-serum-induced activation of platelets. Thromb Res 1997;88:271-281
7. Jeske W, Szatkowski E, Wood JJ, et al. Inhibition of platelet activation in HIT: Thrombin inhibitors vs. antiplalelet agents. Blood 1998;92 (Suppl 1):180a(Abst)
8. Jeske WP, Mousa SA, Yang LH, et al. Short-acting glycoprotein IIb/IIIa inhibitors may be safer for the management of patients with active heparin-induced thrombocytopenic syndrome. Blood 1998;92(Suppl 1):181a(Abst)
9. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-1505
10. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and nonQ-wave myocardial infarction. N Engl J Med 1998; 338:1488-1497
11. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-1435
12. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961
13. The EPILOG Investigators, Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696
14. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443